Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Mar;14(3):377-82.
doi: 10.1093/ntr/ntr143. Epub 2011 Aug 16.

Selegiline transdermal system (STS) as an aid for smoking cessation

Roberta Kahn  1 , Liza Gorgon, Karen Jones, Frances McSherry, Elbert D Glover, Robert M Anthenelli, Thomas Jackson, Jill Williams, Cristin Murtaugh, Ivan Montoya, Elmer Yu, Ahmed Elkashef
Affiliations
Randomized Controlled Trial

Selegiline transdermal system (STS) as an aid for smoking cessation

Roberta Kahn et al. Nicotine Tob Res. 2012 Mar.

Abstract

Introduction: This study examined the efficacy and safety of selegiline transdermal system (STS) and brief repeated behavioral intervention (BRBI) for smoking cessation in heavy smokers. We hypothesized that the quit rate of subjects who received STS and BRBI would be significantly greater than that of those who received placebo patch and BRBI.

Methods: This was a double-blind, placebo-controlled parallel-group study in which 246 men and women were randomized to receive either STS (n = 121) or placebo patch (n =125) for 9 weeks. Recruitment targeted heavy smokers, defined as individuals with self-reported use of ≥15 cigarettes/day in the 30 days prior to enrollment, who had smoked cigarettes for the past 5 years, and had an expired CO level ≥9 ppm during screening.

Results: Although STS was well tolerated, the overall results indicated that STS with BRBI was not more effective than placebo plus BRBI for smoking cessation (p = .58).

Conclusions: The results are discussed in relation to interventions for heavy smokers. Although 2 trials using oral selegiline both showed trends toward improved abstinence, these results indicate that STS with BRBI was not an effective aid for smoking cessation at the end of treatment (10 weeks), 14, or 26 weeks.

PubMed Disclaimer

References

    1. Berlin I, Said S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clinical Pharmacology and Therapeutics. 1995;58:444–452. doi:10.1016/0009-9236(95)90058-6. - PubMed
    1. Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction. 2003;98:1403–1407. doi:10.1046/j.1360-0443.2003.00524.x. - PubMed
    1. Cosgrove KP, Batis J, Bois F, Maciejewski PK, Esterlis I, Kloczynski MA, et al. β2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Archives of General Psychiatry. 2009;66:666–676. Retrieved from http://archpsyc.ama-assn.org/cgi/content/full/66/6/666 (last accessed on 6/22/11) - PMC - PubMed
    1. Covey LS, Glassman AH, Stetner F. Depression and depressive symptoms in smoking cessation. Comprehensive Psychiatry. 1990;31:350–354. doi:10.1016/0010-440X(90)90042-Q. - PubMed
    1. Elkashef A, Fudala PJ, Gorgon L, Li SH, Kahn R, Chiang N, et al. Double-blind placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug and Alcohol Dependence. 2006;85:191–197. doi:10.1016/j.drugalcdep.2006.04.010. - PubMed

Publication types